Navigation Links
Researchers find driver of breast cancer stem cell metastasis
Date:7/24/2012

ANN ARBOR, Mich. Researchers at the University of Michigan Comprehensive Cancer Center have found that a cancer gene linked to aggressive spread of the disease promotes breast cancer stem cells. The finding implies a new way to target the behavior of these lethal cells.

The finding involves the cancer gene RhoC, which has previously been shown to promote metastasis of many types of cancer. RhoC levels increase as breast cancer progresses and high levels of RhoC are associated with worse patient survival.

Cancer stem cells are the small number of cells within a tumor that are believed to fuel the tumor's growth and spread. Researchers believe traditional chemotherapy and radiation treatments often become ineffective because they do not kill the cancer stem cells, and that the key to future treatments is to develop drugs that target and kill these cells.

This new study, which appears online in PLoS ONE, suggests a new way to get at the cancer stem cells.

"Targeting the specific molecular cogs driving the cancer stem cell machinery responsible for the cancer spreading has potential for future treatments. Eliminating cancer stem cells may ultimately be necessary to cure certain cancers, but in the meantime, we may be able to manage the cancer stem cell population and the invasive behaviors of these cells by disrupting the molecular machinery, using RhoC as a target," says senior study author Sofia D. Merajver, M.D., Ph.D., professor of internal medicine and epidemiology at the University of Michigan and scientific director of the breast oncology program at the U-M Comprehensive Cancer Center.

The researchers looked at breast cancer cell lines that were highly metastatic and cell lines from normal breast tissue. By inhibiting or overexpressing RhoC, they found that RhoC expression is necessary to cause metastasis in both cell lines, and that RhoC overexpression alone can cause metastasis. The researchers also tested this in mice and had similar results.

Merajver's lab, in conjunction with other U-M researchers, is studying a novel small molecule drug to inhibit RhoC, which has shown promising initial results in the laboratory. The researchers are continuing to develop this inhibitor, which will require several years of additional testing in the laboratory before potentially advancing to clinical trials.

Breast cancer statistics: 229,060 Americans will be diagnosed with breast cancer this year and 39,920 will die from the disease, according to the American Cancer Society


'/>"/>
Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. Researchers unfold the mechanisms underlying blood disorders
2. New lipid screening guidelines for children overly aggressive, UCSF researchers say
3. BUSM researchers identify genetic markers for testosterone, estrogen level regulation
4. UGA researchers develop rapid diagnostic test for pathogens, contaminants
5. Moffitt Cancer Center researchers find potential key to new treatment for mantle cell lymphoma
6. Researchers link Kawasaki Disease in childhood with increased risk of adult heart disease
7. Researchers to use novel metabolomics technology for COPD
8. Researchers hit back at early bodycheck theory
9. Cleveland Clinic researchers discover molecule that may prevent atherosclerosis
10. Researchers developing new multiple sclerosis drug that can be taken orally
11. UMass Amherst researchers unravel secrets of parasites replication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... ... states in the U.S. require dental technicians to be certified or obtain continuing ... industry, NADL created the “What’s In Your Mouth?” campaign to inform dentists and ...
(Date:2/7/2016)... ... February 07, 2016 , ... Women's Excellence staff, in all four locations, wore ... Wear Red Day is the first Friday each February and a day to bring ... in 3 deaths among women each year – more than all cancers combined. Go ...
(Date:2/7/2016)... ... 2016 , ... Dr. Todd Hobgood , certificated in ... surgical expertise. Technically known as deoxycholic acid or previously as ATX-101, Kybella® ... for reduction of fat below the chin (aka the “double chin”). Medication side ...
(Date:2/6/2016)... ... ... US Sports Camps is proud to sponsor the Bay Area Disc Association's ... leaders, ultimate organizations, and coaches from around the US. The theme for this year’s ... of Youth and Education, describes this year YUCC as “an important conversation we must ...
(Date:2/6/2016)... , ... February 06, 2016 , ... Shark Finds ... announce the launch of a new DRTV campaign with Belly Bands. , Having a ... everything from sprays to puppy pads and find nothing works, get Belly Bands, ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... 2016  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... quarter and year-end 2015 results after the Nasdaq market ... host a live conference call and webcast to discuss ... afternoon, February 11, 2016 at 4:30 p.m. Eastern Time ... --> http://www.neurocrine.com . --> Participants can ...
(Date:2/8/2016)... DUBLIN , Feb. 8, 2016 ... addition of the "Global Skin Protective Equipment ... --> http://www.researchandmarkets.com/research/fqx6nz/global_skin ) has announced ... Equipment Market 2016-2020" report to their offering. ... ( http://www.researchandmarkets.com/research/fqx6nz/global_skin ) has announced the addition of ...
(Date:2/8/2016)... Intarcia Therapeutics, Inc. today announced the appointment of ... created role of Vice President, Head of Global Medical ... of leadership experience at leading pharmaceutical, biotechnology, and health ... Most recently Dr. Yee served as VP, Head of ... Officer at AstraZeneca, where he led medical affairs across ...
Breaking Medicine Technology: